Family Risk, Genetic Counseling & Presymptomatic Testing
At a Glance
For most familial Alzheimer-like prion diseases, a parent with a confirmed disease-causing PRNP variant has a 50% chance of passing it to each child. Inheriting the variant does not guarantee symptoms, so genetic counseling is important before testing or family-planning decisions.
Discovering that a loved one has a genetic prion disease often triggers a second, deeply personal crisis: the realization that you or your children may also be at risk. Because these conditions are caused by variations in the PRNP gene, they can be passed down through generations. Navigating this risk is a complex emotional journey, but you do not have to do it alone. Specialized genetic counseling is the standard of care to help you understand your risks and decide if, or when, you want to know your own genetic status [1][2].
Understanding the Inheritance Pattern
Most genetic prion diseases follow an autosomal dominant inheritance pattern. This means that if one parent carries a confirmed pathogenic variant, there is a 50% chance in each pregnancy that it will be passed to the child [1].
However, inheriting the variant does not always mean a person will definitely get the disease. Doctors use the term penetrance to describe the likelihood that a person with the variant will develop symptoms during their lifetime [3][4].
- Variable Penetrance: Penetrance depends on the exact variant, age, family, and ascertainment. For example, D178N outcomes depend in part on codon 129 and the associated syndrome, and OPRI and V210I penetrance estimates vary by the exact variant. It is important to use mutation-specific estimates from a genetics professional rather than broad categories [5][6][7].
- Individual Variation: Even within the same family, the age of onset (when symptoms start) and the disease course can vary significantly, often modified by other genetic factors like codon-129 [8][9]. However, codon-129 only modifies the phenotype; it does not determine whether a relative inherited the disease-causing variant.
The Process of Presymptomatic Testing
Presymptomatic testing (testing a person before they have symptoms) is a profound decision that should never be rushed. Because there is currently no cure, the decision to test is often about gaining information for life planning rather than medical treatment [10][11].
Predictive testing is most informative only after a pathogenic familial variant has been confirmed in an affected relative. A variant of uncertain significance (VUS) should not be used for predictive testing. Testing of asymptomatic minors is generally deferred when there is no childhood medical benefit.
To protect your well-being, many specialized centers recommend a structured process [12][13]:
- Genetic Counseling: You will meet with a counselor to discuss the science, the exact familial variant, and the limitations of the test [14].
- Psychological Evaluation: While practices vary and it is not necessarily an absolute gatekeeper, many centers offer psychological support to help you explore how you might handle a result and ensure you have a strong support system in place [12].
- The Testing Decision: There is no “right” answer. Many people choose to wait years before testing, while others feel that “knowing is better than not knowing” [15][16].
- Result Disclosure: Results are often delivered in person by a team that can provide immediate support and follow-up care, though practices vary [12][17].
The Psychological Impact on Families
The weight of a genetic diagnosis affects everyone in the family, whether they choose to be tested or not.
- The Burden of Uncertainty: Living “at-risk” can cause significant anxiety. Research shows that even those who decide not to test, or those who test negative (noncarriers), may continue to experience “survivor guilt” or ongoing worry about other family members [15][18].
- Privacy and Discrimination: In the United States, GINA (Genetic Information Nondiscrimination Act) provides some protections against genetic discrimination in health insurance and employment. However, GINA does not cover life, disability, or long-term-care insurance, and does not apply in every context; laws differ elsewhere. Your counselor will discuss these impacts [14][17].
Options for Family Planning
For those who wish to have children but want to prevent passing the variant to the next generation, there are several options to discuss with a genetic reproductive specialist [12][16]:
- Preimplantation Genetic Testing (PGT-M): This involves using In Vitro Fertilization (IVF) to test embryos for the PRNP variant before they are implanted. While this reduces the chance of selecting an affected embryo, it does not completely “ensure” an unaffected child, as IVF may yield no suitable embryo and testing has technical limitations [12][1].
- Prenatal Testing: Confirmatory testing during pregnancy (such as through CVS or amniocentesis, performed at different gestational ages) to determine if the variant was passed on [12].
- Other Paths: Families may also consider egg or sperm donation, adoption, or choosing not to have biological children [12].
Every family’s journey is unique. Whether you choose to test or simply want to understand the risks better, a specialized neurogenetics team can provide the roadmap you need to make the decisions that are right for you.
Common questions in this guide
If a parent carries a PRNP variant, what is my chance of inheriting it?
What does penetrance mean for familial Alzheimer-like prion disease?
How does presymptomatic testing for a familial PRNP variant work?
What family-planning options can lower the chance of passing on a PRNP variant?
Could genetic testing affect my insurance or employment in the United States?
How can families cope with uncertainty about genetic prion disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the exact name and number of the PRNP mutation identified in our family (e.g., 5-OPRI, Y157X, etc.)?
- 2.Can you refer us to a specialized neurogenetics center or a genetic counselor with experience specifically in prion diseases?
- 3.Based on this specific mutation and our family history, what is the 'penetrance'—how likely is it that a carrier will actually develop symptoms in their lifetime?
- 4.What is the codon-129 status of the affected person, and how might that influence the risk or symptoms for other family members?
- 5.If I decide to get tested, what specific protocols do you have for delivering results and providing psychological support afterward?
- 6.Are there reproductive specialists you work with who can explain options like PGT-M (preimplantation genetic testing) for our family?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (18)
- 1
Genetic counseling for prion disease: Updates and best practices.
Goldman JS, Vallabh SM
Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(10)):1993-2003 doi:10.1016/j.gim.2022.06.003.
PMID: 35819418 - 2
Application of a framework to guide genetic testing communication across clinical indications.
Hallquist MLG, Tricou EP, Ormond KE, et al.
Genome medicine 2021; (13(1)):71 doi:10.1186/s13073-021-00887-x.
PMID: 33926532 - 3
Quantifying prion disease penetrance using large population control cohorts.
Minikel EV, Vallabh SM, Lek M, et al.
Science translational medicine 2016; (8(322)):322ra9 doi:10.1126/scitranslmed.aad5169.
PMID: 26791950 - 4
Mortality of Individuals With PRNP Variants Associated With Prion Disease in the United States, 1998-2024.
Lian Y, Kotobelli K, Glisic K, et al.
Neurology. Genetics 2026; (12(5)):e200423 doi:10.1212/NXG.0000000000200423.
PMID: 42662715 - 5
Mortality of individuals with antemortem genetic testing for PRNP variants in the United States, 1998-2024.
Lian Y, Kotobelli K, Glisic K, et al.
medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.10.03.25337271.
PMID: 41256127 - 6
Amino Acid Substitution within Seven-Octapeptide Repeat Insertions in the Prion Protein Gene Associated with Short-Term Course.
Chen Z, Nan H, Kong Y, et al.
Viruses 2022; (14(10)) doi:10.3390/v14102245.
PMID: 36298800 - 7
Characterization of Prion Disease Associated with a Two-Octapeptide Repeat Insertion.
Brennecke N, Cali I, Mok TH, et al.
Viruses 2021; (13(9)) doi:10.3390/v13091794.
PMID: 34578375 - 8
Pooled analysis of patients with inherited prion disease caused by two- to twelve-octapeptide repeat insertions in the prion protein gene (PRNP).
Van den Broecke A, Decruyenaere A, Schuermans N, et al.
Journal of neurology 2024; (271(1)):263-273 doi:10.1007/s00415-023-11968-9.
PMID: 37689591 - 9
Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations.
Llorens F, Zarranz JJ, Fischer A, et al.
Current neurology and neuroscience reports 2017; (17(4)):30 doi:10.1007/s11910-017-0743-0.
PMID: 28324299 - 10
Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations.
Crook A, Williams K, Adams L, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(7-8)):475-485 doi:10.1080/21678421.2017.1332079.
PMID: 28585888 - 11
Experiences of predictive genetic testing in inherited motor neuron disease: Findings from a qualitative interview study.
Howard J, Forrest Keenan K, Mazanderani F, et al.
Journal of genetic counseling 2025; (34(1)):e1904 doi:10.1002/jgc4.1904.
PMID: 38628040 - 12
A Practice Framework for Genetic Testing in Asymptomatic Relatives of Patients With Creutzfeldt-Jakob Disease: Experience and Insights From Israel.
Shir D, Bregman N, David AB, et al.
European journal of neurology 2026; (33(6)):e70649 doi:10.1111/ene.70649.
PMID: 42333775 - 13
Familial Creutzfeldt-Jakob Disease: Case report and role of genetic counseling in post mortem testing.
Clift K, Guthrie K, Klee EW, et al.
Prion 2016; (10(6)):502-506 doi:10.1080/19336896.2016.1254858.
PMID: 27929804 - 14
Defining the Critical Components of Informed Consent for Genetic Testing.
Ormond KE, Borensztein MJ, Hallquist MLG, et al.
Journal of personalized medicine 2021; (11(12)) doi:10.3390/jpm11121304.
PMID: 34945775 - 15
Genetic Testing in Prion Disease: Psychological Consequences of the Decisions to Know or Not to Know.
Schwartz M, Brandel JP, Babonneau ML, et al.
Frontiers in genetics 2019; (10()):895 doi:10.3389/fgene.2019.00895.
PMID: 31616476 - 16
Familial Creutzfeldt-Jakob Disease Cluster Among an African American Family.
Johnson MG, Bradley KK, Coffman RL, Belay ED
Journal of public health management and practice : JPHMP 2017; (23(6)):614-617 doi:10.1097/PHH.0000000000000464.
PMID: 27997483 - 17
Human Genetics Society of Australasia Position Statement: Genetic Carrier Testing for Recessive Conditions.
Vears DF, Boyle J, Jacobs C, et al.
Twin research and human genetics : the official journal of the International Society for Twin Studies 2023; (26(2)):188-194 doi:10.1017/thg.2023.15.
PMID: 37226803 - 18
Genetic counseling for early onset and familial dementia: Patient perspectives on exome sequencing.
Rolf B, Blue EE, Bucks S, et al.
Journal of genetic counseling 2021; (30(3)):793-802 doi:10.1002/jgc4.1379.
PMID: 33393146
This page is for informational purposes only and does not constitute medical advice. A qualified genetic counselor or neurogenetics team can help interpret your family’s PRNP-related risk and support testing or reproductive decisions.
Get notified when new evidence is published on Familial Alzheimer-like prion disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.